Vildagliptin: the first innovative DDP-4 inhibitor
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presenteda...
Guardado en:
Autor principal: | |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ab778ef5d4d43219fab7fe831ded6ca |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|